198 related articles for article (PubMed ID: 115998)
21. Comparative effect of Mycobacterium bovis- and neuraminidase-treated tumor cells on the growth of established methylcholanthrene fibrosarcomas in syngeneic mice.
Rios A; Simmons RL
Cancer Res; 1972 Jan; 32(1):16-21. PubMed ID: 4550256
[No Abstract] [Full Text] [Related]
22. The activation of tumoricidal properties in macrophages of endotoxin responder and nonresponder mice by liposome-encapsulated immunomodulators.
Fogler WE; Talmadge JE; Fidler IJ
J Reticuloendothel Soc; 1983 Mar; 33(3):165-74. PubMed ID: 6834360
[TBL] [Abstract][Full Text] [Related]
23. Characterization of immunosuppressor cells in rats immunized with solubilized tumor-associated antigens prepared from a methylcholanthrene-induced fibrosarcoma.
Minami A; Kasai M; Mizushima Y; Takeichi N; Hosokawa M; Kobayashi H
Cancer Res; 1980 Jul; 40(7):2129-34. PubMed ID: 6446378
[TBL] [Abstract][Full Text] [Related]
24. Activation of mouse peritoneal macrophages during infection with Salmonella typhimurium does not result in enhanced intracellular killing.
Langermans JA; van der Hulst ME; Nibbering PH; van Furth R
J Immunol; 1990 Jun; 144(11):4340-6. PubMed ID: 2111344
[TBL] [Abstract][Full Text] [Related]
25. Activated macrophages and the antitumor action of BCG.
Alexander P
Natl Cancer Inst Monogr; 1973 Dec; 39():127-33. PubMed ID: 4595313
[No Abstract] [Full Text] [Related]
26. The stimulatory effect of tumor bearing upon the T- and B-cell subpopulations of the mouse spleen.
Konda S; Nakao Y; Smith RT
Cancer Res; 1973 Oct; 33(10):2247-56. PubMed ID: 4147496
[No Abstract] [Full Text] [Related]
27. Corynebacterium parvum-induced resistance to a methylcholanthrene fibrosarcoma.
Gupta JD; Morahan PS; Kaplan AM
J Reticuloendothel Soc; 1978 Jan; 23(1):1-9. PubMed ID: 627989
[No Abstract] [Full Text] [Related]
28. Adoptive transfer of immunity against solid fibrosarcoma in mice with splenocytes and peritoneal exudate cells obtained after in vitro sensitization and in vivo immunization with cis-dichlorodiamine platinum(II) treated fibrosarcoma cells.
Sodhi A; Tandon P; Sarna S
Arch Geschwulstforsch; 1985; 55(1):47-61. PubMed ID: 3872651
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of guinea pig cancer with BCG.
Zbar B
Johns Hopkins Med J Suppl; 1974; 3():121-30. PubMed ID: 4608693
[No Abstract] [Full Text] [Related]
30. Tumor-specific resistance in mice detected by inhibition of macrophage migration.
Vaage J; Jones RD; Brown BW
Cancer Res; 1972 Apr; 32(4):680-7. PubMed ID: 4552377
[No Abstract] [Full Text] [Related]
31. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
32. Divergent changes in antimicrobial activity after immunologic activation of mouse peritoneal macrophages.
van Dissel JT; Stikkelbroeck JJ; van den Barselaar MT; Sluiter W; Leijh PC; van Furth R
J Immunol; 1987 Sep; 139(5):1665-72. PubMed ID: 2957432
[TBL] [Abstract][Full Text] [Related]
33. Specific and nonspecific antitumor immunity. II. Macrophage-mediated nonspecific effector activity induced by BCG and similar agents.
Germain RN; Williams RM; Benacerraf B
J Natl Cancer Inst; 1975 Mar; 54(3):709-20. PubMed ID: 1091741
[TBL] [Abstract][Full Text] [Related]
34. Tumour resistance of mice infected with salmonella enteritidis 11RX. The role of peritoneal exudate cells.
Ashley MP; Hardy D
Aust J Exp Biol Med Sci; 1973 Dec; 51(6):801-9. PubMed ID: 4596243
[No Abstract] [Full Text] [Related]
35. Macrophage function in tumor-bearing mice: tumoricidal and chemotactic responses of macrophages activated by infection with Mycobacterium bovis, strain BCG.
Meltzer MS; Stevenson MM
J Immunol; 1977 Jun; 118(6):2176-81. PubMed ID: 325142
[No Abstract] [Full Text] [Related]
36. The development of cellular immunity to tumor cells.
Cerilli J; Smith MC
Surg Gynecol Obstet; 1972 May; 134(5):739-45. PubMed ID: 5064081
[No Abstract] [Full Text] [Related]
37. Identification of macrophage-mediated cytolytic activity as a tumor suppressive mechanism during maintenance of the L5178Y-tumor dormant state in DBA/2 mice.
Robinson MK; Wheelock EF
J Immunol; 1981 Feb; 126(2):673-9. PubMed ID: 7451990
[No Abstract] [Full Text] [Related]
38. The role of activated macrophages in specific and nonspecific cytostasis of tumor cells.
Krahenbuhl JL; Remington JS
J Immunol; 1974 Aug; 113(2):507-16. PubMed ID: 4210882
[No Abstract] [Full Text] [Related]
39. The effects of tumor bearing upon changes in cell distribution and membrane antigen characteristics in murine spleen and thymus cell subpopulations.
Konda S; Smith RT
Cancer Res; 1973 Aug; 33(8):1878-84. PubMed ID: 4541721
[No Abstract] [Full Text] [Related]
40. Defective tumoricidal capacity of macrophages from A/J mice. III. Genetic analysis of the macrophage defect.
Boraschi D; Meltzer MS
J Immunol; 1980 Mar; 124(3):1050-3. PubMed ID: 6987306
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
